TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

Publication Date

2025

Content Type

Article

PubMed ID:

40885199

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS